Decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection?

Clinical Infectious Diseases

Volumn 47, Issue 1, 2008, Pages 63-65

  Kuijper, Ed J ^a   Wilcox, Mark H ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; METRONIDAZOLE; OPIATE; VANCOMYCIN; ANTIINFECTIVE AGENT;

BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CLINICAL EFFECTIVENESS; CLOSTRIDIUM DIFFICILE; DISEASE SEVERITY; DOSE RESPONSE; EPIDEMIC; HUMAN; LOW DRUG DOSE; MORTALITY; NOTE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT RESPONSE; DRUG EFFECT; MICROBIOLOGY; PSEUDOMEMBRANOUS COLITIS; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; METRONIDAZOLE; TREATMENT OUTCOME; VANCOMYCIN;

EID: 46249085217     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/588294     Document Type: Note

References (25)

1. Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006; 12(Suppl 6):2-18.
2. Barbut F, Mastrantonio P, Delmée M, et al. Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin Microbiol Infect 2007; 13:1048-57
3. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171: 466-72.
4. Centers for Disease Control and Prevention. Infection control in healthcare settings. Available at: http://www.cdc.gov/ncidod/dhqp/index.html. Accessed 3 May 2008.
5. Kuijper EJ, Coignard B, Brazier JS, et al. Update of Clostridium difficile-associated disease due to PCR ribotype 027 in Europe. Euro Surveill 2007; 12:E1-2.
6. Fenner L, Widmer AF, Stranden A, et al. First cluster of clindamycin-resistant Clostridium difficile PCR ribotype 027 associated disease in Switzerland. Clin Microbiol Infect 2008; 14:514-5.
7. Goorhuis A, Van der Kooi T, Vaessen N, et al. Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands. Clin Infect Dis 2007; 45:695-703.
8. Pépin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40:1591-7.
9. Freeman J, Baines SD, Saxton K, Wilcox MH. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. J Antimicrob Chemother 2007; 60: 83-91.
10. Goorhuis A, Debast SB, van Leengoed LAMF, et al. Clostridium difficile PCR ribotype 078: an emerging strain in humans and in pigs? J Clin Microbiol 2008; 46:1157-8 [letter].
11. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40:1586-90.
12. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27: 1169-72.
13. Baird D. Comparison of two oral formulations of vancomycin for treatment of diarrhoea associated with Clostridium difficile. J Antimicrob Chemother 1989; 23:167-9.
14. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302-7.
15. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-9.
16. Lamontagne F, Labbé AC, Haeck O, et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 2007; 245:267-72.
17. Al-Nassir WN, Sethi AK, Riggs MM, Bobulsky GS, Jump RLP, Donskey CJ. Comparison of clinical and microbiologic response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 2008; 47:56-62 (in this issue).
18. Ellames D, Wilcox M, Fawley W, Freeman J, Smith C. Comparison of risk factors and outcome of cases of Clostridium difficile infection due to ribotype 027 versus other types [abstract K-605]. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2007.
19. Nagy E, Földes J. Inactivation of metronidazole by Enterococcus faecalis. J Antimicrob Chemother 1991; 27:63-70
20. Rafii F, Wynne R, Heinze TM, et al. Mechanism of metronidazole-resistance by isolates of Enterococcus gallinarum and Enterococcus casseliflavus from the human intestinal tract. FEMS Microbiol Lett 2003; 225:195-200.
21. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. Heath Protection Report 2008; 2. Available at: http://www.hpa.org.uk/hpr/archives/2008/news.htm#1. Accessed 3 May 2008.
22. Aspevall O, Lundberg A, Burman LG, Akerlund T, Svenungsson B. Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital. Antimicrob Agents Chemother 2006; 50:1890-2.
23. Poilane I, Cruaud P, Torlotin JC, Collignon A. Comparison of the E test to the reference agar dilution method for antibiotic susceptibility testing of Clostridium difficile. Clin Microbiol Infect 2000; 6:155-6.
24. van den Berg RJ, Schaap I, Templeton KE, Klaassen CH, Kuijper EJ. Typing and subtyping of Clostridium difficile isolates by using multiple-locus variable-number tandem-repeat analysis. J Clin Microbiol 2007; 45:1024-8.
25. Pépin J, Valiquette L, Gagnon S, Routhier S, Brazeau I. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 2007; 102:2781-8.